Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $171.1852W HIGH $253.12
Volume
435.38 K
Value Traded
203.20 M
Short % Float
3.26%
Days to Cover
3.4
+4.1%Week
+8.04%1 Month
+8.07%3 Month
+30.69%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
27.76 B
EPS (TTM)
10.23
P/E Ratio
24.62
Ent. Value
32.58 B
Total Shares
110.33 M
Float Shares
109.49 M
Insiders
0.48%
Institutions
97.97%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
DGX Catalyst Timeline
Dated clinical, regulatory and corporate events for Quest Diagnostics Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Quest Diagnostics Inc.
113Total events
9Upcoming
14Tier-1 (high impact)
2016 to 2027Coverage
Upcoming catalysts 2
Event history 50
●PublicationPresentation
Study in Hypertension finds current PA screening thresholds may miss half of patients
primary aldosteronismsource ↗
▲PublicationPresentation
Study published in The Journal of Molecular Diagnostics showing Haystack MRD clinical performance in DYNAMIC colorectal cancer specimens
colorectal cancersource ↗
▲Full ResultsClinical Data
Haystack MRD showed 100% sensitivity/specificity at 3-year and 83.3% sensitivity/100% specificity at 5-year follow-up in DYNAMIC cohort
stage II and III colorectal cancersource ↗
▲Biomarker DataClinical Data
Haystack MRD showed 100% sensitivity/specificity at 3-year and 83.3% sensitivity/100% specificity at 5-year follow-up in DYNAMIC cohort
stage II and III colorectal cancersource ↗
●PublicationPresentation
Study 'Coseropositivity to Tick-Borne Pathogens Among Patients Suspected to Have Lyme Disease' published in JAMA Network Open
Lyme disease and other tick-borne pathogen co-exposuresource ↗
●PublicationPresentation
Study published in O&G Open linking BV to increased STI co-infection
bacterial vaginosissource ↗
▲Timing GuidancePresentation
Congressional Problem Solvers caucus issued statement calling for RESULTS Act passage
▲Other Regulator MilestoneEx-US Regulatory
New York State approval granted for Haystack MRD test
cancersource ↗
▲Partnership / LicenseCorporate
Quest Diagnostics integrates Haystack MRD and CGP tests into OncoEMR MPI via pilot program with AON
oncologysource ↗
◆Product LaunchPost-Market
Quest plans full nationwide launch of OncoEMR MPI integration
oncologysource ↗
▲Other Regulator MilestoneEx-US Regulatory
New York State Department of Health CLEP approval for Haystack MRD
solid tumor cancerssource ↗
▲Partnership / LicenseCorporate
Research collaboration with City of Hope to study Haystack MRD for cancer monitoring
solid tumor cancerssource ↗
▲Trial InitiationTrial
City of Hope initiates multi-year research program evaluating Haystack MRD across multiple solid tumors
Breast, colorectal, ovarian, and prostate cancersource ↗
▲Product LaunchPost-Market
Quest plans to launch full OncoEMR MPI integration to providers nationwide
oncologysource ↗
◆Oral PresentationPresentation
Quest Diagnostics to speak at Leerink 2026 Global Healthcare Conference
▲Product LaunchPost-Market
Launch of Quest Flow Cytometry MRD for Myeloma blood test
multiple myelomasource ↗
◆Oral PresentationPresentation
Quest Diagnostics presentation at 44th Annual J.P. Morgan Healthcare Conference
▲FDA Feedback ReceivedFDA Meeting
FDA draft guidance on MRD as primary endpoint for accelerated approval in multiple myeloma
multiple myelomasource ↗
▲Product LaunchPost-Market
Launched AI Companion tool to help patients understand lab test reports
▲Product LaunchPost-Market
Tailored Quest lab test panel purchasable via Apple Health app to be available to public
▲Partnership / LicenseCorporate
Completed acquisition of select dialysis testing assets from Fresenius Medical Care
▲PublicationAD-DetectPresentation
Published data on confirmatory accuracy of two Quest AD-Detect tests in Neurology Clinical Practice
Alzheimer's diseasesource ↗
▲Breakthrough Therapy DesignationDesignation
FDA breakthrough device designation for Haystack MRD test
cancersource ↗
▲Partnership / LicenseCorporate
Collaborations with Mass General Brigham and Rutgers Cancer Institute to trial Haystack MRD
cancersource ↗
▲PublicationPresentation
Publication of landmark study on non-operative management of dMMR solid tumors using Haystack MRD
locally advanced mismatch repair-deficient (dMMR) solid tumorssource ↗
◆Quarterly UpdateCorporate
Reaffirmed full year 2025 guidance and updated Q1 2025 outlook due to weather headwind
▲Breakthrough Therapy DesignationDesignation
FDA granted Haystack MRD Dx Breakthrough Device Designation for Stage II colorectal cancer
Stage II colorectal cancersource ↗
▲Partnership / LicenseCorporate
Health plan collaborations with Elevance Health and Sentara Health Plans took effect
▲PublicationPresentation
NEJM study on immunotherapy response in mismatch repair-deficient cancers found Haystack MRD a reliable liquid biopsy surrogate
mismatch repair-deficient cancerssource ↗
●Poster PresentationPresentation
Analytical validation of Haystack MRD assay poster presented at Association for Molecular Pathology 2024 Annual Meeting
solid tumorsource ↗
●Quarterly UpdateCorporate
Updates full year 2024 guidance: revenues $9.80B-$9.85B, adjusted EPS $8.85-$8.95
▲Partnership / LicenseCorporate
Completed eight acquisitions in 2024 including LifeLabs in Canada
▲Product LaunchAD-DetectPost-Market
Added p-tau217 and p-tau181 biomarkers to AD-Detect blood test menu
Alzheimer's diseasesource ↗
Past FDA Catalysts and PDUFA Decisions
How DGX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Quest Diagnostics Inc. is a diagnostics company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every DGX program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| PFEIFFER GARY MDirector | Sell | -1,203 29,802 held | $243.00 | 10/26/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in DGX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| INTEGRAL HEALTH ASSET MANAGEMENT, LLC | 1.7 % (183.3 %) | 42.39 M | 200.00 K | 233.33% ( 140.00 K) |
DGX Institutional Ownership Trends
DGX Short Interest
Shares sold short, counted twice a month.
3.26%
Short % of Float
of tradable shares sold short
3.6M
Shares Sold Short
+4.6% vs prior count
3.4 Moderate
Days to Cover
trading days of normal volume to buy every short share back
1.1M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How DGX ranks across every disease it competes in
Competitive Position is a premium feature
See how DGX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialDGX News
-DGX
Oct 22, 2026Quest Diagnostics Reports Third Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026
Quest Diagnostics reported third quarter 2026 revenues of $3.10 billion, a 10% increase from the previous year. The company also announced a 28.7% rise in reported EPS to $2.78. Due to strong performance, Quest raised its full year revenue guidance to between $12.065 billion and $12.105 billion. New initiatives include a partnership with Apple for lab test purchases.
Read more →-DGX
Oct 19, 2026Current Screening Thresholds May Miss Half of Patients with Primary Aldosterone, a Leading Cause of Severe High Blood Pressure, Finds Study in Hypertension
A recent study published in Hypertension indicates that current screening guidelines for primary aldosteronism (PA) may lead to the under-diagnosis of half of affected patients. Researchers found that using broader diagnostic criteria could double the detection rate, potentially identifying thousands of high-risk individuals. The findings emphasize the need for revised guidelines to facilitate earlier diagnosis and treatment of this serious condition.
Read more →-DGX
Oct 1, 2026Haystack MRD® Demonstrates Robust Clinical Performance in Specimen Cohort from the Landmark DYNAMIC Colorectal Cancer Trials
The Haystack MRD test has demonstrated exceptional clinical performance in detecting residual and recurrent colorectal cancer, achieving 100% sensitivity and specificity at 3-year follow-up. This study, published in The Journal of Molecular Diagnostics, highlights its superiority over traditional biomarkers and its potential to guide personalized treatment decisions. The test's analytical performance has been validated across multiple solid tumor types.
Read more →-DGX
Sep 30, 2026Who We Play For and Myelai Launch Heart Screening Program at Quest Diagnostics in Tampa as Florida Becomes First State to Require ECGs for High School Athletes
A new cardiac screening program has been launched in Tampa, Florida, in partnership with Who We Play For, Myelai, and Unless Health. This initiative provides ECG screenings for high school athletes, addressing the requirement set by Florida's Second Chance Act. The program aims to screen up to 1,000 students by late November, enhancing the detection of undiagnosed heart conditions.
Read more →-DGX
Sep 22, 2026Quest Diagnostics to Release Third Quarter Financial Results on October 22, 2026
Quest Diagnostics has announced that it will release its third quarter financial results on October 22, 2026, before the market opens. A conference call to discuss these results will take place at 8:30 a.m. Eastern Time on the same day. Participants can access the call via phone or online, with replays available after the event.
Read more →-DGX
Sep 21, 2026Nearly 1 in 3 Patients with Suspected Lyme Disease are Co-Positive for Other Tick-Borne Pathogens, Finds Study by Quest Diagnostics
A study by Quest Diagnostics reveals that nearly one in three patients with Lyme disease antibodies also test positive for other tick-borne pathogens. The research analyzed over 193,000 test results, indicating significant co-exposure patterns, particularly in the Northeast U.S. These findings stress the need for comprehensive testing to ensure accurate diagnoses and effective treatment plans.
Read more →-DGX
Sep 16, 2026Nine in 10 Voters Express Concern That Medicare Lab Payment Cuts Will Harm Patient Access to Diagnostic Lab Testing, Finds National Survey from Quest Diagnostics
A national survey reveals that 96% of American voters value diagnostic lab tests for healthcare, with 83% having relied on them in the past two years. Concerns are rising over scheduled Medicare payment cuts set to take effect in January 2027, which could significantly impact patient access, particularly for seniors and those with chronic conditions. The bipartisan RESULTS Act aims to stabilize Medicare lab payment rates and has garnered substantial support from both voters and advocacy groups.
Read more →-DGX
Sep 9, 2026Apple Health app Users to be Able to Order Labs from Quest Diagnostics
Quest Diagnostics has announced that Apple Health app users will soon be able to order lab tests directly through the app. This integration allows users to purchase a panel of over 50 biomarkers, aimed at enhancing preventive health insights. Users can schedule blood draws at Quest's service centers and receive results within the app, promoting better health management.
Read more →-DGX
Aug 25, 2026Quest Diagnostics to Speak at the Baird 2026 Global Healthcare Conference
Quest Diagnostics announced that its CEO, Jim Davis, will speak at the Baird 2026 Global Healthcare Conference. The session will cover the company's strategy, performance, and market trends. The event is scheduled for September 15, 2026, and will be available via live webcast and archived for later access.
Read more →-DGX
Aug 24, 2026Quest Diagnostics to Speak at the Morgan Stanley 24th Annual Global Healthcare Conference
Quest Diagnostics will participate in the Morgan Stanley 24th Annual Global Healthcare Conference, where CFO Sam Samad will discuss the company's strategy and market trends. The event is scheduled for September 14, 2026, and will be available via live webcast. An archived version will also be accessible afterward.
Read more →-DGX
Aug 24, 2026Quest Diagnostics to Offer FDA-Cleared Roche pTau217 Blood Test to Assess Alzheimer's Disease Pathology
Quest Diagnostics has announced the addition of the FDA-cleared Roche pTau217 blood test to its AD-Detect portfolio, enhancing the assessment of Alzheimer's disease. The test is the first single-biomarker blood test approved for both rule-in and rule-out assessments of amyloid pathology. Additionally, Quest is launching a new multi-biomarker test with a low indeterminate rate to improve diagnostic accuracy for symptomatic patients.
Read more →-DGX
Aug 18, 2026WHOOP Makes Advanced Labs Available Without a Wearable Membership
WHOOP has announced the availability of its Advanced Labs services without requiring a membership. This expansion includes the addition of Galleri®, a multi-cancer early detection test developed by GRAIL. The Advanced Labs service, powered by Quest Diagnostics, offers comprehensive blood testing, clinician-reviewed results, and personalized health recommendations.
Read more →-DGX
Aug 12, 2026Quest Diagnostics Declares Quarterly Cash Dividend
Quest Diagnostics has announced a quarterly cash dividend of $0.86 per share, which will be payable on October 21, 2026, to shareholders of record on October 6, 2026. This decision reflects the company's commitment to returning value to its shareholders while maintaining strong operational performance. Quest Diagnostics continues to play a vital role in healthcare through its diagnostic services.
Read more →-DGX
Jul 30, 2026Bacterial Vaginosis Linked to Increased STI Co-Infection, Finds National Study of 1.5 Million Women from Quest Diagnostics
A recent study by Quest Diagnostics found that women with bacterial vaginosis (BV) are over three times more likely to be co-infected with sexually transmitted infections (STIs) compared to those without BV. Analyzing data from over 1.5 million women, the study revealed that 12% of BV-positive women had at least one STI. The findings emphasize the need for STI testing in women diagnosed with BV to prevent serious health complications.
Read more →-DGX
Jul 23, 2026▲ +8.6%on this news
Quest Diagnostics Reports Second Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026
Quest Diagnostics reported strong financial results for the second quarter of 2026, with revenues reaching $3.04 billion, a 10.2% increase from the previous year. The company also raised its full-year guidance for revenues and earnings per share, reflecting robust growth across its service channels. Notable advancements include collaborations in kidney care and significant revenue growth in Advanced Diagnostics.
Read more →-DGX
Jul 8, 2026Quest Diagnostics Now the Largest Clinical Reference Lab to Extend Oncology Test Access Through OncoEMR MPI
Quest Diagnostics has announced the integration of its Haystack MRD test and Comprehensive Genomic Profiling services into OncoEMR, enhancing access for clinicians. This pilot program, in collaboration with the American Oncology Network, aims to streamline test ordering and reporting for cancer care providers. The full integration is set to launch nationwide later this year.
Read more →-DGX
Jun 29, 2026Quest Diagnostics Foundation Commits Nearly $5 Million to Improving Health Outcomes and Food Security in Miami-Dade County, Florida
The Quest Diagnostics Foundation has announced a nearly $5 million grant to four local organizations in Miami-Dade County to improve health outcomes and food security. The initiative aims to reach 15,000 residents over two years, providing no-cost laboratory testing and support services. Collaborating organizations will focus on chronic diseases and maternal health, enhancing access to healthcare in vulnerable communities.
Read more →-DGX
Jun 25, 2026Days After Launch, Attunio Health Expands Precision Psychiatry Infrastructure with Quest Diagnostics and Getlabs
Attunio Health has expanded its AI-powered precision psychiatry platform by partnering with Quest Diagnostics and Getlabs. This collaboration allows for advanced diagnostic testing and at-home blood collection, enhancing accessibility to mental healthcare. The initiative aims to provide continuous, data-driven psychiatric care, moving beyond traditional methods reliant on episodic visits.
Read more →-DGX
Jun 24, 2026Quest Diagnostics Receives New York State Approval for Haystack MRD®, Broadening Patient Access to ctDNA Minimal Residual Disease Testing
Quest Diagnostics has received approval from the New York State Department of Health for its Haystack MRD test, which detects minimal residual disease in patients with solid tumors. This approval allows the test to be used in all 50 states, enhancing access for patients and providers. The test's effectiveness has been validated in clinical studies, demonstrating its potential to improve patient management.
Read more →-DGX
Jun 18, 2026UTI-causing Bacteria Resistant to Current Drugs, Finds National Study by Hackensack Meridian CDI and Quest Diagnostics
A new study published in Nature Communications reveals that nearly 70% of Klebsiella pneumoniae strains, responsible for UTIs and other infections, are resistant to commonly used antibiotics. Conducted by Hackensack Meridian CDI and Quest Diagnostics, the research indicates a troubling shift as these bacteria spread beyond hospitals into communities. The findings underscore the urgent need for new treatment options and ongoing surveillance.
Read more →About Quest Diagnostics Inc.
Headquarters500 PLAZA DRIVE, SECAUCUS, NJ, 07094
BIOPHARMAWATCH ELITE PLUS
Trade the next DGX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime